Skip to main content

Table 1 Demographic and clinical variables for SLE patients in discovery and validation cohorts

From: A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis

 

Discovery

Validation

Demographic variables

SLE Active LN (n = 60)

SLE Active non-LN (n = 25)

Healthy controls (n = 24)

SLE Active LN (n = 33)

SLE Active non-LN (n = 16)

SLE Remission LN (n = 30)

Age

 Range (years)

18–64

18–61

23–47

18–56

19–67

19–67

 Mean ± SD (median)

35.5 ± 12.7 (32)

30.0 ± 11.9 (26)

32.8 ± 6.7 (31)

28.5 ± 9.5 (27)

36.8 ± 15.9 (36)

40.0 ± 13.6 (40.5)

Gender, n (%) female

46 (82.1)

22 (88)

21 (87.5)

28 (84.8)

15 (93.8)

28 (93.3)

Ethnicity, n (%)

 Caucasian

29 (48.3)

9 (36)

14 (58.3)

14 (42.4)

6 (37.5)

20 (66.7)

 African Canadian

14 (23.3)

7 (28)

1 (4.2)

8 (24.2)

2 (12.5)

4 (13.3)

 Asian

9 (15)

5 (20)

3 (12.5)

5 (11.6)

2 (12.5)

2 (6.7)

 Othera

8 (13.3)

4 (16)

6 (25)

6 (18.2)

6 (37.5)

4 (13.3)

Clinical featuresb, n (%)

 Rash

8 (14.3)

12 (48)

N/A

11 (33.3)

3 (18.8)

0

 Mucocutaneous

9 (16.1)

9 (36)

N/A

0

2 (12.5)

0

 Alopecia

4 (7.1)

7 (28)

N/A

4 (12.1)

5 (31.2)

1 (3.3)

 Arthritis

13 (23.2)

13 (52)

N/A

3 (9.1)

9 (56.2)

0

 Serositis

8 (14.3)

4 (16)

N/A

2 (6.1)

1 (6.2)

0

 Myositis

1 (1.8)

0

N/A

0

1 (6.2)

0

 Hematological

6 (10.7)

6 (24)

N/A

2 (6.1)

3 (18.8)

0

 Fever

3 (5.4)

1 (4)

N/A

1 (3.0)

2 (12.5)

0

 Nephritis (≥1 or more SLEDAI-2 K criteria)

59 (98.3)c

0

N/A

33 (100)

0

1 (3.3)

 Vasculitis

3 (5.4)

7 (28)

N/A

2 (6.1)

3 (18.8)

0

SLEDAI-2 K, mean ± SD (median)

15.6 ± 7.4 (16)

10.1 ± 4.7 (10)

N/A

14.2 ± 5.6 (14)

7.2 ± 2.7 (8)

1.7 ± 1.9 (1)

Creatinine, mean ± SD (median)

118.0 ± 78.8 (87)

64.5 ± 9.6 (62)

N/A

91.8 ± 81.1 (69)

69.2 ± 16.0 (70.5)

81.8 ± 25.3 (75.5)

Medicationsb

 Prednisone (mg/day), mean ± SD (median)

28.5 ± 20.8 (30)

10.8 ± 30.4 (0)

N/A

21.8 ± 18.8 (15)

8.5 ± 13.2 (4)

6.1 ± 6.9 (4)

 Anti-malarials, n (%)

31 (55.4)

15 (60)

N/A

21 (63.6)

13 (81.2)

24 (80)

 Immunosuppressives, n (%)

55 (91.7)

5 (20)

N/A

27 (81.8)

10 (62.5)

22 (73.3)

  Azathioprine, n (%)

9 (16.1)

3 (12)

N/A

11 (33.3)

3 (18.8)

9 (30)

  Mycophenolate mofetil, n (%)

15 (26.8)

1 (4)

N/A

9 (27.3)

2 (12.5)

10 (33.3)

  Methotrexate, n (%)

1 (1.8)

1 (4)

N/A

1 (3.0)

5 (31.2)

1 (3.3)

  1. In the validation cohort, eight patients had renal biopsies an average of 10 days from sample accrual
  2. aOther ethnicities include Hispanic, Filipino, mixed, and, for three healthy controls, unknown ethnicity
  3. bClinical variables and treatment at time of recruitment
  4. cOne patient had a renal biopsy performed for 0.45 g/24 h proteinuria
  5. LN lupus nephritis, N/A not applicable, SD standard deviation, SLE systemic lupus erythematosus, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index-2000
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us